AMLX - Amylyx Pharmaceuticals, Inc.
IEX Last Trade
3.81
0.025 0.656%
Share volume: 7,507
Last Updated: Fri 27 Dec 2024 08:30:32 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$3.78
0.03
0.66%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-10 | 2023-03-13 | 2023-05-11 | 2023-08-10 | 2023-11-09 | 2024-02-22 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 225.240 M | 181.443 M | 391.453 M | 407.958 M | 453.588 M | 466.584 M | 517.454 M | 417.457 M | |
| Current Assets | 216.139 M | 172.199 M | 382.133 M | 389.053 M | 427.394 M | 434.110 M | 464.666 M | 410.534 M | |
| Inventories | 0.000 | 563.000 K | 9.769 M | 13.075 M | 24.858 M | 32.374 M | 38.323 M | 0.000 | |
| Other Current Assets | 9.458 M | 8.906 M | 10.113 M | 12.749 M | 11.787 M | 17.338 M | 14.931 M | 16.890 M | |
| Short Term Investments | 9.458 M | 8.906 M | 10.113 M | 12.749 M | 11.787 M | 17.338 M | 14.931 M | 16.890 M | |
| Total Receivables | 0.000 | 137.000 K | 15.306 M | 17.555 M | 33.473 M | 29.353 M | 40.050 M | 20.351 M | |
| Current Cash | 206.681 M | 162.593 M | 346.945 M | 345.674 M | 357.276 M | 355.045 M | 371.362 M | 373.293 M | |
| Total Non-current Assets | 9.101 M | 9.244 M | 9.320 M | 18.905 M | 26.194 M | 32.474 M | 52.788 M | 6.923 M | |
| Property Plant Equipment | 1.857 M | 2.118 M | 2.611 M | 2.559 M | 2.637 M | 2.761 M | 2.686 M | 2.459 M | |
| Other Assets | 6.825 M | 6.407 M | 5.990 M | 15.627 M | 22.838 M | 28.994 M | 49.383 M | 3.745 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 225.240 M | 181.443 M | 391.453 M | 407.958 M | 453.588 M | 466.584 M | 517.454 M | 417.457 M | |
| Total liabilities | 32.451 M | 37.415 M | 50.846 M | 55.310 M | 67.223 M | 48.184 M | 84.022 M | 93.021 M | |
| Total current liabilities | 27.164 M | 32.647 M | 46.609 M | 51.616 M | 64.082 M | 45.617 M | 82.042 M | 91.639 M | |
| Accounts Payable | 8.117 M | 7.052 M | 6.257 M | 10.770 M | 24.695 M | 6.371 M | 22.061 M | 21.453 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 1.787 M | 1.990 M | 2.040 M | 2.093 M | 2.146 M | 2.201 M | 2.257 M | 2.312 M | |
| Long term debt | 5.287 M | 4.768 M | 4.237 M | 3.694 M | 3.141 M | 2.567 M | 1.980 M | 1.382 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 192.789 M | 144.028 M | 340.607 M | 352.648 M | 386.365 M | 418.400 M | 433.432 M | 324.436 M | |
| Common stock | 58.276 M | 58.533 M | 65.569 M | 66.717 M | 67.234 M | 67.415 M | 67.572 M | 67.854 M | |
| Retained earnings | -257.760 M | -311.516 M | -354.220 M | -352.647 M | -330.573 M | -309.680 M | -304.949 M | -423.742 M |